Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01965613 · ClinicalTrials.gov registry record · Phase 2
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01965613 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 10 participants.
The verdict
NCT01965613, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
Interventions
- BIOLOGICAL Xilonix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01965613
The ClinicalTrials.gov registry entry for NCT01965613 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xilonix is the first listed.
NCT01965613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01965613 about?
NCT01965613 is a clinical study titled "A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum". The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
What is the current status of trial NCT01965613?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2014-01-31. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT01965613?
The interventions under investigation include: Xilonix (BIOLOGICAL).
Who is sponsoring clinical trial NCT01965613?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.